开云app官网登录入口网页版-官方正版

#ErbB2#

11篇内容 | 1052人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2222405, encodeId=54cd2222405ea, content=<a href='/topic/show?id=942b4516096' target=_blank style='color:#2F92EE;'>#子宫内膜癌#</a> <a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=ERBB2（HER2）突变子宫内膜癌的临床病理和分子特征及生存结局, objectType=article, longId=840507, objectId=1d3c84050ed3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240714/1720949737178_5579292.jpg, objectUrl=/article/show_article.do?id=1d3c84050ed3, replyNumber=0, likeNumber=35, createdTime=2024-08-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1d3c84050ed3, moduleTitle=ERBB2（HER2）突变子宫内膜癌的临床病理和分子特征及生存结局, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1d3c84050ed3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1662187, encodeId=f8c8166218e53, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, objectType=article, longId=732001, objectId=e4e7e32001b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e7e32001b1, replyNumber=0, likeNumber=92, createdTime=2022-07-27, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e7e32001b1, moduleTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e4e7e32001b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662186, encodeId=7a6b16621862a, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌, objectType=article, longId=730595, objectId=f470e305957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f470e305957c, replyNumber=0, likeNumber=65, createdTime=2022-08-17, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f470e305957c, moduleTitle=JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f470e305957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662185, encodeId=52d51662185d5, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=JAMA Oncol：ERBB2低表达乳腺癌是否可划分成独特的组织亚型？, objectType=article, longId=730602, objectId=4989e306029b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4989e306029b, replyNumber=0, likeNumber=85, createdTime=2023-06-02, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4989e306029b, moduleTitle=JAMA Oncol：ERBB2低表达乳腺癌是否可划分成独特的组织亚型？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4989e306029b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662184, encodeId=a42916621849c, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=JAMA Oncol：仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗！, objectType=article, longId=300545, objectId=1df2300545a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1df2300545a4, replyNumber=0, likeNumber=93, createdTime=2022-10-03, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1df2300545a4, moduleTitle=JAMA Oncol：仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1df2300545a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662183, encodeId=8cc916621834b, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=Cell Death Diff：抑制ErbB2内吞降解的去泛素化酶USP2可作为ErbB2阳性乳腺癌的治疗靶标, objectType=article, longId=193625, objectId=599e1936251e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=599e1936251e, replyNumber=0, likeNumber=71, createdTime=2020-11-24, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=599e1936251e, moduleTitle=Cell Death Diff：抑制ErbB2内吞降解的去泛素化酶USP2可作为ErbB2阳性乳腺癌的治疗靶标, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=599e1936251e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662181, encodeId=06b51662181ef, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=CLIN CANCER RES：不同黑色素瘤亚型的ERBB2突变率, objectType=article, longId=155768, objectId=935a155e6853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=935a155e6853, replyNumber=0, likeNumber=72, createdTime=2019-04-17, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=935a155e6853, moduleTitle=CLIN CANCER RES：不同黑色素瘤亚型的ERBB2突变率, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=935a155e6853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662182, encodeId=00e9166218281, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=Diabetes Care：循环HER2/ErbB2水平与糖尿病发病率增加相关, objectType=article, longId=168550, objectId=ddd016855018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddd016855018, replyNumber=0, likeNumber=73, createdTime=2019-08-06, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddd016855018, moduleTitle=Diabetes Care：循环HER2/ErbB2水平与糖尿病发病率增加相关, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ddd016855018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662180, encodeId=400f1662180e3, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=Cancer Res：CD73促进HER2/ErbB2抗体治疗耐药, objectType=article, longId=118368, objectId=3d5c11836860, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d5c11836860, replyNumber=0, likeNumber=71, createdTime=2018-03-22, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d5c11836860, moduleTitle=Cancer Res：CD73促进HER2/ErbB2抗体治疗耐药, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3d5c11836860)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662179, encodeId=567d16621e954, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=JAMA：ERBB2(HER2)阳性转移性乳腺癌治疗中，曲妥珠单抗生物仿制药的效果与曲妥珠单抗的效果等效吗？, objectType=article, longId=83429, objectId=1e488342901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e488342901, replyNumber=0, likeNumber=96, createdTime=2017-04-09, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e488342901, moduleTitle=JAMA：ERBB2(HER2)阳性转移性乳腺癌治疗中，曲妥珠单抗生物仿制药的效果与曲妥珠单抗的效果等效吗？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1e488342901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662178, encodeId=fcbc16621e8f2, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=JAMA：乳腺癌的ERBB2 (HER2) 检测病例问答，来试试？, objectType=article, longId=65657, objectId=04886565ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04886565ee9, replyNumber=0, likeNumber=79, createdTime=2016-05-27, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04886565ee9, moduleTitle=JAMA：乳腺癌的ERBB2 (HER2) 检测病例问答，来试试？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=04886565ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1662177, encodeId=e26916621e748, content=<a href='/topic/show?id=a9556923d7' target=_blank style='color:#2F92EE;'>#ErbB2#</a>, objectTitle=Cancer Res：郭亚军研发出双特异性抗ErbB2抗体TPL, objectType=article, longId=25045, objectId=c60d2504504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c60d2504504, replyNumber=0, likeNumber=74, createdTime=2014-06-22, rootId=0, userName=ms7514935887898259, userId=612025370618, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c60d2504504, moduleTitle=Cancer Res：郭亚军研发出双特异性抗ErbB2抗体TPL, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c60d2504504)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ErbB2

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#子宫内膜癌# #ErbB2#

ERBB2（HER2）突变子宫内膜癌的临床病理和分子特征及生存结局

2024-08-25发表于上海

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果

2022-07-27

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

JAMA Oncol：伊匹单抗 vs FOLFOX联合纳武单抗和曲妥珠单抗治疗ERBB2阳性胃食管腺癌

2022-08-17

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

JAMA Oncol：ERBB2低表达乳腺癌是否可划分成独特的组织亚型？

2023-06-02

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

JAMA Oncol：仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗！

2022-10-03

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

Cell Death Diff：抑制ErbB2内吞降解的去泛素化酶USP2可作为ErbB2阳性乳腺癌的治疗靶标

2020-11-24

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

CLIN CANCER RES：不同黑色素瘤亚型的ERBB2突变率

2019-04-17

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

Diabetes Care：循环HER2/ErbB2水平与糖尿病发病率增加相关

2019-08-06

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

Cancer Res：CD73促进HER2/ErbB2抗体治疗耐药

2018-03-22

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

JAMA：ERBB2(HER2)阳性转移性乳腺癌治疗中，曲妥珠单抗生物仿制药的效果与曲妥珠单抗的效果等效吗？

2017-04-09

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

JAMA：乳腺癌的ERBB2 (HER2) 检测病例问答，来试试？

2016-05-27

ms7514935887898259 (审核中...)

前往app查看评论内容

#ErbB2#

Cancer Res：郭亚军研发出双特异性抗ErbB2抗体TPL

2014-06-22

科室
- - 订阅+
  - 更多科室
工具
服务